Drugs for Hypercalcemia, Infantile, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 42)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Salmon calcitonin |
Approved, Investigational |
Phase 4 |
|
47931-85-1 |
155817456 |
Synonyms:
CALCITONIN (SALMON SYNTHETIC)
Calcitonin salmon
CALCITONIN SALMON RECOMBINANT
Calcitonin, salmon
Calcitonina salmón sintética
|
Calcitonin-salmon
CT (salmon)|Miacalcin®
FORTICAL
Recombinant salmon calcitonin
Salmon calcitonin
|
|
2 |
|
Ergocalciferol |
Approved, Nutraceutical |
Phase 4 |
|
50-14-6 |
5280793 |
Synonyms:
(+)-Vitamin D2
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(E,2R,5R)-5,6-DIMETHYLHEPT-3-EN-2-YL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENECYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(E,2R,5R)-5,6-DIMETHYLHEPT-3-EN-2-YL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(E,1R,4R)-1,4,5-TRIMETHYLHEX-2-ENYL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-1-CYCLOHEXANOL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(E,1R,4R)-1,4,5-TRIMETHYLHEX-2-ENYL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-{2-[(1R,3AS,4E,7AR)-1-[(2R,3E,5R)-5,6-DIMETHYLHEPT-3-EN-2-YL]-7A-METHYL-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXAN-1-OL
(3b,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(3Î’,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,secoergosta-5,7,10(19)-ol
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3ah)-indanylidene]ethylidene]-cyclohexanol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
Activated ergosterol
beta-Ol
Buco-D
Calciferol
CALCIFEROL IN ARACH OIL
Calciferols
Calciferon 2
CALTRATE
Condacaps
Condocaps
Condol
Crtron
Crystallina
D2, Vitamin
Daral
D-Arthin
Davitamon D
Davitin
Decaps
Dee-osterol
Dee-ron
Dee-ronal
Dee-roual
delta-Arthin
Deltalin
delta-Tracetten
De-rat concentrate
Deratol
Detalup
D-FORTE
Diactol
Divit urto
Doral
Drisdol
D-Tracetten
ECIFEROL D2
Ercalciol
|
Ergocalciferol
ERGOCALCIFÉROL
Ergocalciferol oil
Ergocalciferols
Ergocalciferolum
ERGO-D2
ERGORAL D2
Ergorone
Ergosterol activated
Ergosterol irradiated
Ertron
Fortodyl
Geltabs
Hi-deratol
Infron
Irradiated ergosta-5,7,22-trien-3beta-ol
LANES
Metadee
Mina D2
Mulsiferol
Mykostin
Novovitamin-D
NSC-62792
Oleovitamin D
OLEOVITAMIN D, SYNTHETIC
Oleovitamin D2
Osteil
Ostelin
OSTO-D2
Radiostol
Radstein
Radsterin
Rodine C
Shock-ferol
Shock-ferol sterogyl
Sterogyl
STEROGYL 15H
STEROGYL-15
Synthetic vitamin D
Uvesterol D
Uvesterol-D
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in oil
VITAMIN D
Vitamin D 2
Vitamin D2
Vitamina D2
Vitavel-D
|
|
3 |
|
Calcitriol |
Approved, Nutraceutical |
Phase 4 |
|
32222-06-3 |
5280453 |
Synonyms:
(1a,3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(1R,3S,5Z)-5-{2-[(1R,3AS,4E,7AR)-1-[(2R)-6-HYDROXY-6-METHYLHEPTAN-2-YL]-7A-METHYL-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXANE-1,3-DIOL
(1S,3R,5Z,7E)-9,10-Seco-5,7,10(19)-cholestatriene-1,3,25-triol
(1S,3R,5Z,7E)-9,10-Secocholesta-5,7,10-triene-1,3,25-triol
(1Α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trienetriol
(5Z,7E)-(1S,3R)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
1 alpha, 25 Dihydroxy 20 epi vitamin D3
1 alpha, 25-Dihydroxy-20-epi-vitamin D3
1 alpha,25 Dihydroxycholecalciferol
1 alpha,25 Dihydroxyvitamin D3
1 alpha,25-Dihydroxycholecalciferol
1 alpha,25-Dihydroxyvitamin D3
1,25 Dihydroxy 20 epi vitamin D3
1,25 Dihydroxycholecalciferol
1,25 Dihydroxyvitamin D3
1,25(OH)2-20EPi-D3
1,25-DHCC
1,25-Dihydroxy-20-epi-vitamin D3
1,25-Dihydroxycholecalciferol
1,25-Dihydroxyvitamin D
1,25-Dihydroxyvitamin D3
1a,25(OH)2D3
1a,25-(OH)2D3
1a,25-Dihydroxycholecalciferol
1a,25-Dihydroxyvitamin D3
1a,25-Dihydroxyvitamin D3 / 1a,25-dihydroxycholecalciferol / calcitriol
1-a-25-Dihydroxyvitamin D3
1alpha,25(OH)2D3
1alpha,25-Dihydroxycholecalciferol
1alpha,25-Dihydroxyvitamin D3
1-alpha,25-Dihydroxyvitamin D3
1-alpha-25-Dihydroxyvitamin D3
1Α,25(OH)2D3
1Α,25-dihydroxycholecalciferol
1Α,25-dihydroxyvitamin D3
1Α,25-dihydroxyvitamin D3 / 1α,25-dihydroxycholecalciferol / calcitriol
1-Α-25-dihydroxyvitamin D3
20 Epi 1alpha,25 dihydroxycholecaliferol
20-Epi-1alpha,25-dihydroxycholecaliferol
25-Dihydroxycholecalciferol
5-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
Abbott brand OF calcitriol
alpha,25-Dihydroxyvitamin D3, 1
Alphapharm brand OF calcitriol
Bocatriol
Calcijex
Calcijex®|calcitriol|Rocaltrol®
|
Calcitriol
Calcitriol abbott brand
Calcitriol alphapharm brand
Calcitriol cryopharma brand
Calcitriol galderma brand
Calcitriol gry brand
Calcitriol jenapharm brand
Calcitriol kyramed
Calcitriol kyramed brand
Calcitriol leo brand
Calcitriol medice brand
Calcitriol nefro
Calcitriol renacare brand
Calcitriol roche brand
Calcitriol-nefro
CalcitriolNefro
Calcitriolum
Cryopharma brand OF calcitriol
D3, 1 alpha,25-Dihydroxyvitamin
D3, 1,25-Dihydroxy-20-epi-vitamin
D3, 1,25-Dihydroxyvitamin
Decostriol
DIHYDROXYCHOLECALCIFEROL
DIHYDROXYVITAMIN D 3
Dihydroxyvitamin D3
Galderma brand OF calcitriol
Gry brand OF calcitriol
Hoffmann la roche brand OF calcitriol
Hoffmann-la roche brand OF calcitriol
Jenapharm brand OF calcitriol
KyraMed brand OF calcitriol
KyraMed, calcitriol
Leo brand OF calcitriol
Medice brand OF calcitriol
Osteotriol
RenaCare brand OF calcitriol
Renatriol
Ro 21-5535
RO-215535
RO-21-5535
Rocaltrol
Roche brand OF calcitriol
Silkis
Sitriol
Soltriol
Tirocal
Topitriol
Toptriol
VECTICAL
|
|
4 |
|
Calcitonin gene-related peptide |
Investigational |
Phase 4 |
|
83652-28-2 |
91976570 |
Synonyms:
2-{[2-({6-amino-2-[(2-{[2-({2-[(2-{[2-({[1-(2-{[2-({2-[(2-{[6-amino-2-({2-[(2-{[2-({2-[(2-{[2-({2-[(2-{[2-({2-[(2-{[2-({2-[(2-{[2-({2-[({19-[(2-amino-1-hydroxypropylidene)amino]-16-(carboxymethyl)-6,9,12,15,18-pentahydroxy-7,13-bis(1-hydroxyethyl)-10-methyl-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-4-yl}(hydroxy)methylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1,3-dihydroxybutylidene]amino}-1-hydroxy-3-(1H-imidazol-5-yl)propylidene)amino]-5-carbamimidamido-1-hydroxypentylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1-hydroxypropylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1-hydroxy-4-methylpentylidene)amino]-1,3-dihydroxypropylidene}amino)-5-carbamimidamido-1-hydroxypentylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxyethylidene]amino}-1-hydroxy-3-methylbutylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1-hydroxyhexylidene]amino}-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene)amino]-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene}amino)-1-hydroxy-3-phenylpropylidene]amino}-3-methylbutanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-1,3-dihydroxybutylidene]amino}-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1-hydroxyethylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxyhexylidene}amino)-1-hydroxypropylidene]amino}-3-phenylpropanoate
Calcitonin gene related peptide
Calcitonin-gene-related peptide
|
|
|
5 |
|
Calcitonin |
|
Phase 4 |
|
|
|
Synonyms:
4-{[1-({1-[(5-amino-1-{[1-({1-[(1-{[1-(2-{[4-carbamimidamido-1-({2-hydroxy-1-[(1-{[2-hydroxy-1-({[(2-hydroxy-1-{[({3-hydroxy-1-[2-(C-hydroxycarbonimidoyl)pyrrolidin-1-yl]-1-oxobutan-2-yl}-C-hydroxycarbonimidoyl)methyl]-C-hydroxycarbonimidoyl}ethyl)-C-hydroxycarbonimidoyl]methyl}-C-hydroxycarbonimidoyl)propyl]-C-hydroxycarbonimidoyl}-2-(C-hydroxycarbonimidoyl)ethyl)-C-hydroxycarbonimidoyl]propyl}-C-hydroxycarbonimidoyl)butyl]-C-hydroxycarbonimidoyl}pyrrolidin-1-yl)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-C-hydroxycarbonimidoyl}-2-hydroxypropyl)-C-hydroxycarbonimidoyl]-3-(C-hydroxycarbonimidoyl)propyl}-C-hydroxycarbonimidoyl)-3-methylbutyl]-C-hydroxycarbonimidoyl}pentyl)-C-hydroxycarbonimidoyl]-2-(1H-imidazol-5-yl)ethyl}-C-hydroxycarbonimidoyl)-3-methylbutyl]-C-hydroxycarbonimidoyl}-4-({2-[(2-{[2-({6-amino-2-[(2-{[2-({2-[({22-amino-6,9,12,15,18,21-hexahydroxy-16-[(C-hydroxycarbonimidoyl)methyl]-7-(1-hydroxyethyl)-10,19-bis(hydroxymethyl)-13-(2-methylpropyl)-1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosa-5,8,11,14,17,20-hexaen-4-yl}(hydroxy)methylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1-hydroxyethylidene)amino]-1-hydroxyhexylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene}amino)butanoate
Calcihexal
Calcimar
CALCITARE
CALCITONIN
Calcitonin salmon
CALSYNAR
Cibacalcin
Forcaltonin
|
Fortical
Miacalcic
Miacalcin
Recombinant salmon calcitonin
Salcatonin
Salmon calcitonin
Salmon calcitonin (1-32)
Synthetic salmon calcitonin
|
|
6 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
7 |
|
Katacalcin |
|
Phase 4 |
|
|
16172926 |
8 |
|
Vitamin D2 |
|
Phase 4 |
|
|
3249 |
Synonyms:
Calciferols
D2, Vitamin
Ergocalciferol
|
Ergocalciferols
Vitamin D 2
Vitamin D2
|
|
9 |
|
Ergocalciferols |
|
Phase 4 |
|
|
|
10 |
|
Trace Elements |
|
Phase 4 |
|
|
|
11 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
12 |
|
Micronutrients |
|
Phase 4 |
|
|
|
13 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
14 |
|
Tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
15 |
|
Cinacalcet |
Approved |
Phase 3 |
|
226256-56-0 |
156419 |
Synonyms:
(R)-alpha-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
(R)-a-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
(R)-Α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
073, AMG
1493, KRN
alpha-Methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-naphthalenemethanamine, (alphar)-hydrochloride
AMG 073
AMG-073
AMG-073|Mimpara®|Sensipar®
|
CINACALCET
Cinacalcet hydrochloride
CNC
Hydrochloride, cinacalcet
KRN1493
KRN-1493
Mimpara
N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine
Sensipar
|
|
16 |
|
Melanocyte-Stimulating Hormones |
|
Phase 2, Phase 3 |
|
|
|
17 |
|
Adrenocorticotropic Hormone |
|
Phase 2, Phase 3 |
|
|
|
18 |
|
beta-Endorphin |
|
Phase 2, Phase 3 |
|
|
|
Synonyms:
|
19 |
|
Neurotransmitter Agents |
|
Phase 2, Phase 3 |
|
|
|
20 |
|
Endorphins |
|
Phase 2, Phase 3 |
|
|
|
21 |
|
Denosumab |
Approved |
Phase 2 |
|
615258-40-7 |
|
Synonyms:
AMG-162
Denosumab
PROLIA
PROLIA, RANMARK XGEVA
|
PROLIA, XGEVA
TK006
TK-006
XGEVA
|
|
22 |
|
Calcium carbonate |
Approved, Investigational |
Phase 2 |
|
471-34-1 |
|
Synonyms:
Aragonite
CaCO3
Calcio carbonato
Calcite
Calcium carbonate
Calcium carbonate (1:1)
Calcium carbonate, precipitated
Calcium carbonic acid
Calcium carbonic acid (1:1)
Calcium carbonic acid, precipitated
Calcium milk
Calciumcarbonat
Cal-sup
Carbonate calcium salt (1:1)
Carbonate de calcium
|
Carbonate, calcium
Carbonato de calcio
Carbonic acid calcium salt (1:1)
Carbonic acid de calcium
Chalk
e 170
Kalziumkarbonat
Kohlensaurer kalk
Limestone
Marble
Milk OF calcium
Precipitated calcium carbonate
Precipitated calcium carbonic acid
Vaterite
|
|
23 |
|
Rifampicin |
Approved |
Phase 2 |
|
13292-46-1 |
135512673 5381226 135900090 |
Synonyms:
2,15,17,23,27,29-Hexahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-{[(4-methylpiperazin-1-yl)imino]methyl}-6-oxo-8,30-dioxa-24-azatetracyclo[23.3.1.1,.0,]triaconta-1(28),2,4,9,19,21,23,25(29),26-nonaen-13-yl acetic acid
3-(((4-METHYL-1-PIPERAZINYL)IMINO)METHYL)RIFAMYCIN SV
Archidyn
BA-411661E
BA-41166E
Benemycin
EREMFAT
L-5103
L-5103 Lepetit
L-5103-LEPETIT
NIH-10782
NSC-113926
R/AMP
RAMP
Rfamipicin
RFP
Rifa
Rifadin
Rifadin IV
Rifadin®|rifampin
Rifadine
Rifagen
|
Rifaldazin
Rifaldazine
Rifaldin
RIFAMPICIN
Rifampicin SV
Rifampicina
Rifampicine
Rifampicinum
Rifampin
Rifamycin
RIFAMYCIN AMP
Rifaprodin
Rifoldin
Rifoldine
Riforal
Rimactan
Rimactane
Rimactin
Rimazid
Rofact
Tubocin
|
|
24 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
25 |
|
Dialysis Solutions |
|
Phase 2 |
|
|
|
26 |
|
Immunoglobulins |
|
Phase 1, Phase 2 |
|
|
|
27 |
|
Antibodies, Monoclonal |
|
Phase 1, Phase 2 |
|
|
|
28 |
|
Antibodies |
|
Phase 1, Phase 2 |
|
|
|
29 |
|
Immunologic Factors |
|
Phase 1, Phase 2 |
|
|
|
30 |
|
Dihydroxyphenylalanine |
|
Phase 2 |
|
|
|
31 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
32 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
33 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
34 |
|
Antitubercular Agents |
|
Phase 2 |
|
|
|
35 |
|
Somatostatin |
Approved, Investigational |
|
|
38916-34-6, 51110-01-1 |
53481605 16129706 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
ALA-GLY-CYCLO-[CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS]
Growth hormone-inhibiting hormone (ghih)
L-ALANYLGLYCYL-L-CYSTEINYL-L-LYSYL-L-ASPARAGINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-CYSTEINE CYCLIC (3-14) DISULFIDE
SOMATOSTATIN
SOMATOSTATIN-1
SOMATOSTATIN-14
SOMATOSTATINA
|
SOMATOSTATINE
SOMATOSTATINUM
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
SRIF-14
SYNTHETIC GROWTH HORMONE RELEASE-INHIBITING HORMONE
SYNTHETIC SOMATOSTATIN-14
|
|
36 |
|
Mineral oil |
Approved, Vet_approved |
|
|
8042-47-5 |
|
Synonyms:
Food Grade Mineral Oil
Heavy Liquid Petrolatum
Heavy mineral oil
Liquid Paraffin
Liquid Petrolatum
Mineral oil
Mineral Oil (high Viscosity)
|
Mineral Oil, Heavy
Paraffin Oil
Paraffin, Liquid
Paraffinum Liquidum
Petrolatum, Liquid
White Mineral Oil
|
|
37 |
|
Vitamin A |
Approved, Nutraceutical, Vet_approved |
|
|
22737-96-8, 68-26-8 |
5280382 445354 |
Synonyms:
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-EN-1-YL)NONA-2,4,6,8-TETRAEN-1-OL
(ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAEN-1-OL
11-CIS-RETINOL
11-cis-Vitamin a alcohol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-e)-isomer
all trans Retinol
all-trans-Retinol
ALL-TRANS-RETINYL ALCOHOL
ALL-TRANS-VITAMIN A ALCOHOL
ALPHALIN
Aquasol a
AROVIT
BETA-RETINOL
B-RETINOL
CHOCOLA A
cis-11-Retinol
|
NEPALM
NSC-122759
OLEOVITAMIN A
Retinol
RETINOL (VIT A)
RETINOL ACETATE
RETINOL PALMITATE
Retinolum
RO-A-VIT
TRANS-RETINOL
Vitamin a
VITAMIN A 1
VITAMIN A OIL
VITAMIN A SOLUBILIZED
Vitamin a1
|
|
38 |
|
Liver Extracts |
|
|
|
|
|
39 |
|
Gastrins |
|
|
|
|
|
40 |
|
Dermatologic Agents |
|
|
|
|
|
41 |
|
Retinol palmitate |
|
|
|
|
|
42 |
|
Diphosphonates |
|
|
|
|
|
Interventional clinical trials:
(show all 47)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Improving the Sensitivity of Sestamibi SPECT-CT Parathyroid Scan With Calcitonin Pre-treatment for Primary Hyperparathyroidism |
Unknown status |
NCT03935984 |
Phase 4 |
Calcitonin |
2 |
Does Treatment of Hypovitaminosis D Increase Calcium Absorption? |
Completed |
NCT00581828 |
Phase 4 |
Vitamin D |
3 |
Effectiveness and Safety of a 6-Month Treatment With IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose |
Completed |
NCT00891813 |
Phase 4 |
Zemplar (paricalcitol) |
4 |
A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients |
Terminated |
NCT01725113 |
Phase 4 |
Calcitriol;Paricalcitol |
5 |
Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate in the Treatment of Breast Cancer Patients With Bone Metastases |
Unknown status |
NCT00326820 |
Phase 3 |
ibandronate sodium;zoledronic acid;Zolendronic Acid |
6 |
ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study |
Unknown status |
NCT02155803 |
Phase 2, Phase 3 |
ACTHAR Gel (adrenocorticotropic hormone) |
7 |
An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Who Are Unable to Undergo Parathyroidectomy or Relapse After Parathyroidectomy |
Completed |
NCT03280264 |
Phase 3 |
KHK7580 |
8 |
A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy |
Completed |
NCT00975221 |
Phase 3 |
Cinacalcet;Placebo |
9 |
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism |
Completed |
NCT00975000 |
Phase 3 |
Cinacalcet;Placebo |
10 |
An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism |
Completed |
NCT01460030 |
Phase 3 |
Cinacalcet HCl |
11 |
Effect of Vitamin D Treatment in Primary Hyperparathyroidism |
Completed |
NCT00674154 |
Phase 2, Phase 3 |
Cholecalciferol |
12 |
Cinacalcet Actions in Familial Primary Hyperparathyroidism |
Completed |
NCT00325104 |
Phase 3 |
|
13 |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 and 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients With Any Cancer With Bone Metastases Other Than Breast Cancer, Multiple Myeloma or Prostate Cancer |
Completed |
NCT00003884 |
Phase 3 |
zoledronic acid |
14 |
A Phase III Randomized, Multicenter Non-Inferiority Trial Evaluating the Efficacy of Oral Ibandronate Versus Intravenous Zoledronate in the Reduction of Skeletal-Related Events in Patients With Metastatic Breast Cancer |
Withdrawn |
NCT00301886 |
Phase 3 |
ibandronate;zoledronate |
15 |
Early Effect of Vitamin D in Primary Hyperparathyroidism |
Withdrawn |
NCT01329666 |
Phase 2, Phase 3 |
|
16 |
A Phase I/II, Single Arm, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory Hypercalcemia of Malignancy |
Unknown status |
NCT04198480 |
Phase 1, Phase 2 |
JMT103 |
17 |
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates |
Completed |
NCT00896454 |
Phase 2 |
denosumab |
18 |
Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients. |
Completed |
NCT00744302 |
Phase 2 |
physiological (1.25 mmol/L ) calcium dialysate |
19 |
A Phase I-II, 24-Week, Multi-Center, Double-Blind, Randomized, Dose-Ranging Study To Evaluate The Safety And Efficacy Of A Humanized Monoclonal Antibody To PTHrP Versus Zoledronic Acid In Patients With Breast Cancer Metastatic To Bone |
Completed |
NCT00060138 |
Phase 1, Phase 2 |
zoledronic acid |
20 |
Studies of Hyperparathyroidism and Related Disorders |
Completed |
NCT00001277 |
Phase 2 |
68Ga-Dotatate;18F-DOPA |
21 |
Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Inactivating Mutations in the CYP24A1 Gene |
Recruiting |
NCT03301038 |
Phase 2 |
Rifampin |
22 |
Cinacalcet for Treatment of Persistent Secondary Hyperparathyroidism in Renal Transplant Recipients: Effect on Renal Function, Serum Calcium and Bone Histomorphometry |
Terminated |
NCT00415584 |
Phase 1, Phase 2 |
Cinacalcet HCl |
23 |
Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Idiopathic Infantile Hypercalcemia |
Recruiting |
NCT03384121 |
Phase 1 |
Rifampin 150 mg, 300 mg capsules and 25 mg/mL oral suspension |
24 |
Comparison of Skeletal and Mineral Metabolism Responses in Healthy African-Americans and Caucasians Using a Continuous Seven-Day Parathyroid Hormone (PTH) or Parathyroid Hormone-related Protein (PTHrP) Infusion |
Withdrawn |
NCT01333267 |
Phase 1 |
Parathyroid Hormone-related Protein (1-36);parathyroid hormone (1-34);PTH (1-34) and PTHrP (1-36) |
25 |
Hypercalcemia After Paraffin Oil Injection: Aetiology, Pathogenesis and Possible Treatment Options |
Unknown status |
NCT04292288 |
|
|
26 |
Myocardial Lipid and Glycogen Metabolism & Cardiac Function in Patients With Impaired Glucose Tolerance or Type 2 Diabetes Mellitus and Calcium Sensing Receptor Mutations - A Cross Sectional Magnetic Resonance Spectroscopy and Imaging Study |
Unknown status |
NCT02023489 |
|
|
27 |
Identification of Differentially Expressed Proteins in Parathyroid Tumors and Their Clinical Correlation With the Disease |
Unknown status |
NCT01647503 |
|
|
28 |
Case-control Study of the PTH Homeostasis in Adolescents and Young Adults With Bartter Syndrome |
Unknown status |
NCT01021280 |
|
|
29 |
A Novel Approach to Ultrafast Parathyroid SPECT Imaging Using a Solid State CZT SPECT Camera |
Unknown status |
NCT01226810 |
|
|
30 |
Zoledronic Acid (Zometa) for the Management of Tumor-induced Hypercalcemia (TIH) and Malignant Bone Pain (MBP) in the Community: A Feasibility Study |
Completed |
NCT00126386 |
|
Zoledronic acid (Zometa) |
31 |
Search for New Genetic Causes of Hypercalcemia by Massively Parallel Sequencing of a Genes Panel |
Completed |
NCT02908542 |
|
|
32 |
Arterial Stiffness and Decreased Bone Buffering Capacity in Hemodialysis Patients |
Completed |
NCT00485706 |
|
|
33 |
Rate of Termination of Commercial Premixed Parenteral Nutrition (PN) in Surgical Patients Secondary to High Serum Electrolyte Levels |
Completed |
NCT04256369 |
|
|
34 |
Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone-related Protein(1-36): Effects on Bone Formation |
Completed |
NCT00580788 |
Early Phase 1 |
PTHrP (1-36) |
35 |
Dissimilar PTH, Gastrin, and Ionized Calcium Response to Oral Peptones in Normocalcemic Primary Hyperparathyroidism, Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects |
Completed |
NCT01042626 |
|
|
36 |
Vitamin D Status in Pregnant Women With Preeclampsia |
Completed |
NCT01648842 |
|
|
37 |
Hypercalcemia After Cosmetic Paraffin Oil Injections: Unravelling Etiology, Pathogenesis and Potential Treatments |
Recruiting |
NCT04265599 |
|
|
38 |
Familial Hypocalciuric Hypercalcemia: Clinical Aspects and Evolution |
Recruiting |
NCT04872894 |
|
|
39 |
Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy |
Recruiting |
NCT04299425 |
|
|
40 |
Registry and Biobank for Patients With Hypoparathyroidism Wuerzburg |
Recruiting |
NCT05585593 |
|
|
41 |
Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy |
Recruiting |
NCT05022641 |
|
|
42 |
Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy |
Active, not recruiting |
NCT05152927 |
|
|
43 |
Preclinic Evaluation of a Vitamin D Analog in Vitamin D 24-hydroxylase Deficiency |
Enrolling by invitation |
NCT04987073 |
|
|
44 |
A Prospective, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules as Determined by Hypercalcemia in Pediatric Patients Ages 0 to 16 With Chronic Kidney Disease (CKD) Stage 5 Receiving Peritoneal Dialysis (PD) Within Current Clinical Practice |
Terminated |
NCT01134315 |
|
Paricalcitol;Calcitriol |
45 |
Cost-Effective Use of Bisphosphonates in Metastatic Bone Disease - A Comparison of Bone Marker Directed Zoledronic Acid Therapy to a Standard Schedule |
Terminated |
NCT00458796 |
|
zoledronic acid |
46 |
Insulin Resistance in Primary Hyperparathyroidism, a Non-classical Manifestation |
Withdrawn |
NCT02711059 |
|
|
47 |
Ultrasound Guided Fine Needle Aspiration of Parathyroid Gland as a Pre Operative Localization Tool to Identify Pathological Parathyroid |
Withdrawn |
NCT03516747 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Calcitonin
Edetic Acid
Edetic Acid, Disodium Salt
EDTA TETRASODIUM
Etidronate
Etidronate Disodium
gallium nitrate
|
pamidronate
Pamidronate Disodium
Prednisone
PREDNISONE PWDR
salmon calcitonin
ZOLEDRONIC
zoledronic acid
|
|